MAP2K7 and melanoma: Moreover, the MEK inhibitor binimetinib (as monotherapy or in combination therapy) has been reported to be effective for patients with NRAS mutant melanoma.343 Recently, the FDA-approved a novel MEK1/2 inhibitor named selumetinib.